| Title |
Does amantadine induce acute psychosis? A case report and literature review
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, April 2016
|
| DOI | 10.2147/ndt.s101569 |
| Pubmed ID | |
| Authors |
Wei-juan Xu, Ning Wei, Yi Xu, Shao-hua Hu |
| Abstract |
Over-the-counter cold medicines, which contain amantadine, are widely used in the People's Republic of China. Clinicians are familiar with the psychosis caused by long-term treatment with amantadine, especially in elderly patients; however, early-onset psychotic complications among healthy young individuals have rarely been reported. This article reports the case of a 28-year-old patient who presented with hallucination-delusion syndrome soon after treatment with cold medicine containing amantadine hydrochloride and acetaminophen. The symptoms resolved completely after a 2-week course of paliperidone treatment. Clinicians should be sensitive to the acute psychotic complications induced by an interaction between amantadine and acetaminophen. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 5% |
| Unknown | 20 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 4 | 19% |
| Student > Master | 2 | 10% |
| Student > Bachelor | 2 | 10% |
| Unspecified | 1 | 5% |
| Other | 1 | 5% |
| Other | 2 | 10% |
| Unknown | 9 | 43% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 24% |
| Psychology | 3 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Chemistry | 1 | 5% |
| Unspecified | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 10 | 48% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 April 2017.
All research outputs
#17,603,147
of 25,805,386 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,897
of 3,150 outputs
Outputs of similar age
#194,569
of 315,688 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#67
of 83 outputs
Altmetric has tracked 25,805,386 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,150 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.7. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,688 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 83 others from the same source and published within six weeks on either side of this one. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.